Compare DexCom, Inc. (DXCM) vs Gogoro Inc (GGR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Gogoro Inc — how do they compare? DexCom, Inc. trades at $90.64 (market cap $33.79B), while Gogoro Inc trades at $2.51 (market cap $52.19M). The key difference: DexCom, Inc. is far larger — about 647.4× Gogoro Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Gogoro Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | GGR | |
|---|---|---|
Market Cap | $33.79B | $52.19M |
Sector | Health | Technology |
52-Week High | $89.53 | $7.50 |
52-Week Low | $54.84 | $2.55 |
Enterprise Value | $33.24B | $354.63M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
GGR trades at $2.46, down 4.65% today, with a bearish technical signal despite oversold RSI readings. The company reported Q1 2026 revenue of $281.48M with negative net income of -$79.97M, though operating cash flow improved to $35.90M. Valuation metrics show low P/S (0.14) and P/B (0.45) ratios, but profitability remains weak with negative ROE (-50.38%) and net margins (-24.68%).
The outlook remains challenging with persistent losses and negative cash flow, though management highlights margin improvements and subscriber growth. Key risks include execution on profitability and competitive pressures. Analyst consensus is neutral (100% Hold), reflecting cautious sentiment amid ongoing turnaround efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Gogoro Inc
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →
